HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Hormone cosmetics

This article was originally published in The Rose Sheet

Executive Summary

FDA withdraws advanced notice of proposed rulemaking for cosmetic products containing certain hormone ingredients effective Nov. 26, as it is no longer considered a viable candidate for further action, the agency reports in a 1Federal Register notice published last year and recently posted on dockets. Action is part of a move to reduce FDA's regulatory backlog. Agency received nine comments relating to the withdrawal of the hormone-containing cosmetics ANPR, some of which argued the move could call into question points raised in the proposed rule and change the marketing status of these products. FDA responds the withdrawal neither affirms nor rejects statements in the preamble, and as the proposed rule, published in 1993 permitting progesterone and pregnenolone in cosmetics in certain concentrations, was never finalized, its withdrawal does not change the marketing status of these products. Agency announced its intention to withdraw the proposed ANPR along with 83 other proposed actions in 2003 (2"The Rose Sheet" April 3, 2003, p. 10)...

You may also be interested in...

Hormone-Containing Cosmetics Rule Should Be Pursued – Advocacy Groups

Progesterone-containing topical cosmetics should be permitted on the market and FDA should pursue a final rule establishing such a policy, according to several alternative medicine and women's health advocacy groups

The Quality Lowdown: On Redeploying Inspectors, API Suppliers Thanks To Coronavirus

US investigators fan out to non-China inspection priorities and Secretary Azar talks supply management; warning letters hit record keeping, investigations and basic GMP compliance.

Mallinckrodt's Opioid Resolution Through Generic Unit Bankruptcy May Be 'Test Case'

Mallinckrodt to pay $1.6bn and place its generics unit in bankruptcy under agreement in principle for US global settlement; six states are not on board, including New York, whose suit is still set to go to trial March 20.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts